Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)

Roger Li, Paras H. Shah, Tyler F. Stewart, Jong Kil Nam, Trinity J. Bivalacqua, Donald L. Lamm, Edward M. Uchio, Daniel M. Geynisman, Joseph M. Jacob, Joshua J. Meeks, Rian Dickstein, Shane M. Pearce, Seok Ho Kang, Seung Il Jung, Ashish M. Kamat, James M. Burke, Kirk A. Keegan, Gary D. Steinberg

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article.

Original languageEnglish
Pages (from-to)2377
JournalNature Medicine
Volume30
Early online dateJun 2 2024
DOIs
StatePublished - Jul 2 2024

Fingerprint

Dive into the research topics of 'Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial (Nature Medicine, (2024), 10.1038/s41591-024-03025-3)'. Together they form a unique fingerprint.

Cite this